More on the Vouchers 1) Regulatory Explainer: E
Post# of 72445
Posted On: 08/24/2015 8:05:18 PM
More on the Vouchers
1) Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers
Posted 02 July 2015
http://www.raps.org/Regulatory-Focus/News/201...ers/#.dpuf
2) Rare Pediatric Disease Priority Review Vouchers (Nov 2014)
http://www.fda.gov/downloads/RegulatoryInform...423325.pdf
And more on Kevetrins potential as an MDM2 Inhibitor
"MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways"
ncotarget. 2014 Apr 30; 5(
: 2030–2043.
Published online 2014 Apr 23.
PMCID: PMC4039142
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039142/
ABSTRACT
While MDM2 inhibitors hold great promise as cancer therapeutics, drug resistance will likely limit their efficacy as single agents. To identify drug combinations that might circumvent resistance, we screened for agents that could synergize with MDM2 inhibition in the suppression of cell viability. We observed broad and robust synergy when combining MDM2 antagonists with either MEK or PI3K inhibitors. Synergy was not limited to cell lines harboring MAPK or PI3K pathway mutations, nor did it depend on which node of the PI3K axis was targeted. MDM2 inhibitors also synergized strongly with BH3 mimetics, BCR-ABL antagonists, and HDAC inhibitors. MDM2 inhibitor-mediated synergy with agents targeting these mechanisms was much more prevalent than previously appreciated, implying that clinical translation of these combinations could have far-reaching implications for public health. These findings highlight the importance of combinatorial drug targeting and provide a framework for the rational design of MDM2 inhibitor clinical trials.
1) Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers
Posted 02 July 2015
http://www.raps.org/Regulatory-Focus/News/201...ers/#.dpuf
2) Rare Pediatric Disease Priority Review Vouchers (Nov 2014)
http://www.fda.gov/downloads/RegulatoryInform...423325.pdf
And more on Kevetrins potential as an MDM2 Inhibitor
"MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways"
ncotarget. 2014 Apr 30; 5(
: 2030–2043. Published online 2014 Apr 23.
PMCID: PMC4039142
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039142/
ABSTRACT
While MDM2 inhibitors hold great promise as cancer therapeutics, drug resistance will likely limit their efficacy as single agents. To identify drug combinations that might circumvent resistance, we screened for agents that could synergize with MDM2 inhibition in the suppression of cell viability. We observed broad and robust synergy when combining MDM2 antagonists with either MEK or PI3K inhibitors. Synergy was not limited to cell lines harboring MAPK or PI3K pathway mutations, nor did it depend on which node of the PI3K axis was targeted. MDM2 inhibitors also synergized strongly with BH3 mimetics, BCR-ABL antagonists, and HDAC inhibitors. MDM2 inhibitor-mediated synergy with agents targeting these mechanisms was much more prevalent than previously appreciated, implying that clinical translation of these combinations could have far-reaching implications for public health. These findings highlight the importance of combinatorial drug targeting and provide a framework for the rational design of MDM2 inhibitor clinical trials.
(0)
(0)